Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,646.40
(
1.31%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
110.46
(
-1.71%
)
Bitcoin
75,802.67
(
0.03%
)
News Focus
News Focus
Post# of 823575
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

CrashOverride

Send PM Follow Ignore
Followers 96
Posts 5080
Boards Moderated 0
Alias Born 02/07/2021

CrashOverride

Re: dr_lowenstein post# 527063

Wednesday, 11/02/2022 12:27:04 PM

Wednesday, November 02, 2022 12:27:04 PM

Post# of 823575
NYAS reviews content of all presentations submitted for consideration. It's required that the presentation goes through peer review before it's accepted by NYAS. DCVax passed peer review.

Mark Reardon, of Harvard and Dana Farber, who ran failed Rindopepimut GBM trial, said the DCVax trial was a great success.

Do your own research. I am not providing legal or investment advice. This is an anonymous forum for entertainment purposes only. Don't trust anything you read.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News